tbuckley/cabot-search huggingface dataset:
LBA28 A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial
Authors: M.R. Mirza, L. Bjørge, F. Marmé, R. DePont Christensen, M. Gil-Martin, A. Auranen, B. Ataseven, M.J. Rubio, V. Salutari, B. Lund, I. Runnebaum, A. Redondo, K. Lindemann, F. Trillsch, M.P. Barretina Ginesta, H. Roed, J. Løhndorf, G-B. Nyvang, J. Sehouli
Journal: Annals of Oncology (2020)
382P The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: Final results from a phase I study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma (GBM)
Authors: C. Tiu, A. Tzankov, R. Plummer, R. Rulach, I. Vivanco, P.J. Mulholland, B. Gurel, I. Figueiredo, N. Md. Haris, S. Anderson, F. Bachmann, M. Engelhardt, T. Kaindl, H. Lane, K. Litherland, C. Pognan, S. Berezowska, J. Evans, R. Kristeleit, J.S. Lopez
Journal: Annals of Oncology (2020)
Hidradenitis Suppurativa Area and Severity Index Revised (HASI‐R): psychometric property assessment*
Authors: N. Goldfarb, M. A. Lowes, M. Butt, T. King, A. Alavi, J. S. Kirby
Journal: British Journal of Dermatology (2020)

Background Validated, reliable, globally accepted outcome measurement instruments for hidradenitis suppurativa (HS) are needed. Current tools to measure the physical signs domain for HS rely on lesion counts, which are time-consuming and unreliable. Objectives To assess the reliability and validity of the Hidradenitis suppurativa Area and Severity Index Revised (HASI-R) tool, a novel method for assessing HS severity, incorporating signs of inflammation and body surface area involved. Methods The measurement properties of the HASI-R tool were evaluated. The tool was created by combining the previously published HASI and Severity and Area Score for Hidradenitis instruments. Twenty raters evaluated 15 patients with HS in a hospital-based ambulatory dermatology clinic. The objectives of the study were to assess inter- and intra-rater reliability of the HASI-R and its components, as well as its construct and known-groups validity. Existing lesion count-based clinician-reported measures of HS and their components were also assessed. Raters were also asked their preferences regarding the various HS severity assessment tools. Results The HASI-R had moderate inter-rater reliability [intra-class correlation coefficients (ICC) 0·60]. This was better than all other HS physical sign outcome measures evaluated, which had poor inter-rater reliability (ICC < 0·5). HASI-R had the highest intra-rater reliability (ICC 0·91). The HASI-R had good construct validity and demonstrated known-groups validity. The HASI-R was also the most preferred tool by all raters. Conclusions Results from the clinometric assessment of the HASI-R are encouraging, and support continued evaluation of this clinician-reported outcome measure.
476P Mutational profiling allows the stratification of metastatic colorectal cancer patients with poor prognosis
Authors: A. Rodriguez Hernandez, S. LaHoz, F.M. Laia, T. Gorría Puga, R. Moreno, F. Esposito, H. Oliveres, S. Albiol Rodriguez, T. Sauri, M. Cuatrecasas, P. Jares, L. Pedrosa, E. Pineda, A. Castells, A. Prat, J. Camps, J. Maurel
Journal: Annals of Oncology (2020)
205P Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen
Authors: L. Braal, K.G.A.M. Hussaarts, L. Seuren, E. Oomen-de Hoop, P. de Bruijn, S.A.J. Buck, M.M.E.M. Bos, M.F. Thijs-Visser, J.M. Zuetenhorst, D. Mathijssen-van Stein, M.B. Vastbinder, R.W.F. van Leeuwen, T. van Gelder, S.L. Koolen, R.H. Mathijssen
Journal: Annals of Oncology (2020)
603TiP Phase II, open-label study of erdafitinib in adult and adolescent patients (pts) with advanced solid tumours harboring fibroblast growth factor receptor (FGFR) gene alterations
Authors: M. Schuler, J. Tabernero, C. Massard, G. Vasudeva Iyer, O. Witt, T. Doi, S. Qin, C. Lu-Emerson, D. Hargrave, J. Garcia-Corbacho, S. Little, Q. Xia, A. Santiago-Walker, C.H. Moy, C. Hammond, Y.Y. Lau, H. Sweiti, S. Pant
Journal: Annals of Oncology (2020)
1321P Advanced lung cancer inflammation index (ALI score) as a biomarker of immunotherapy efficacy in patients with advanced non-small cell lung cancer: A nationwide analysis in Greece
Authors: G. Mountzios, E. Samantas, E. Zervas, S. Angelaki, S. Baka, A. Nikolaidi, A.N. Christopoulou, G. Pentheroudakis, H. Linardou, P. Kosmidis, A. Psyrri, C. Andreadis, E. Fountzilas, C. Emmanouilidis, G. Oikonomopoulos, Z. Saridaki-Zoras, E. Razis, E.I. Perdikouri, I. Boukovinas, K. Syrigos
Journal: Annals of Oncology (2020)
1461P Sex differences in treatment and survival of patients with unresectable or metastatic esophagogastric cancer: A population-based study
Authors: W.P.M. Dijksterhuis, M.C. Kalff, R.H. Verhoeven, A.D. Wagner, V.E.P.P. Lemmens, M.G.H. van Oijen, S.S. Gisbertz, M.I. van Berge Henegouwen, H.W.M. van Laarhoven
Journal: Annals of Oncology (2020)
300P Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study
Authors: E. Zattarin, C. Fabbroni, F. Ligorio, A. Marra, C. Corti, O. Bernocchi, M. Sirico, D.G. Generali, G. Curigliano, G. Bianchi, G. Capri, L. Rivoltini, F.G.M. De Braud, C. Vernieri
Journal: Annals of Oncology (2020)
Successful endoscopic extraction of a missing proximal esophageal foreign body
Authors: Lijuan Yang, Xiao Han, Min Xu, Rong Wan, Xiaobo Cai
Journal: Endoscopy (2020)

A 32-year-old man swallowed a piece of iron wire by mistake approximately 8 weeks before admission. Computed tomography (CT) of the larynx showed a short, high-density strip, judged to be a foreign body (about 6 – 8 mm long at level 6/7 of the cervical vertebra), in the upper esophagus ([Fig. 1]). No abnormal findings resulted from several gastroscopy and laryngoscopy examinations in the local hospital, indicating that the foreign body was embedded under the mucosal layer. The patient was very anxious and insisted doctors remove it.
502P Nivolumab, alone or with ipilimumab, for mismatch repair deficient metastatic colorectal cancer: A United Kingdom multicentre analysis of patient outcomes
Authors: J.J.M. Lam, J. Bridgewater, M. Alani, S. Mullamitha, M. Braun, V. Kunene, S. Baijal, C. Holden, K. Aboud, N. Chopra, C. Lopez Escola, A. Rao, L. Samuel, A. Denton, S.A. Grumett, L. Melcher, S. Muthuramalingam, P. Sankey, M. Saunders, K-K. Shiu
Journal: Annals of Oncology (2020)
1060P HER2-XPAT, a novel protease-activatable pro-drug T-cell engager (TCE), engineered to address on-target, off tumour toxicity and provide large predicted safety margins in non-human primate (NHP)
Authors: F. Cattaruzza, A. Nazeer, Z. Lange, C. Koski, M. Hammond, A. Henkensiefken, D. Hostetter, M. Derynck, V. Schellenberger, B. Irving
Journal: Annals of Oncology (2020)
1462P Prognostic impact of clinical and laboratory nutritional markers in resectable gastroesophageal cancer
Authors: H.C. Puhr, L. Saliternig, A. Steindl, M. Paireder, R. Asari, S.F. Schoppmann, A.S. Berghoff, M. Preusser, A. Ilhan-Mutlu
Journal: Annals of Oncology (2020)
187P Impact of oncotype DX on agreement and confidence in adjuvant treatment decision making in breast cancer
Authors: L. Licata, G. Viale, C. Criscitiello, A. Giordano, M. Chavez-MacGregor, G. Curigliano, J. Foldi, O. Oke, M. Giuliano, R.J. Collins, L. Del Mastro, F. Puglisi, F. Montemurro, C. Vernieri, L. Gerratana, S. Barnato Giordano, A. Rognone, L. Sica, L. Pusztai, G. Bianchini
Journal: Annals of Oncology (2020)
767P Neutrophil-to-lymphocyte ratio (NLR) and systemic inflammation index (SII) as prognostic factors in advanced urinary tract carcinoma patients treated with atezolizumab: Subanalysis of the Italian population of the SAUL study
Authors: S.E. Rebuzzi, C.N. Sternberg, G.L. Banna, P. Ermacora, F. Morelli, F. Nolè, L. Marandino, S. Panni, F. Massari, A. Hamzaj, L. Milesi, D. Santini, M. De Tursi, M. Scartozzi, C. Astolfi, G. Fornarini
Journal: Annals of Oncology (2020)
Treatment of acquired hemophilia A, a balancing act: results from a 27‐year Dutch cohort study
Authors: Sarah J. Schep, Wobke E. M. van Dijk, Erik A. M. Beckers, Karina Meijer, Michiel Coppens, Jeroen Eikenboom, Frank W. G. Leebeek, Lize F. D. van Vulpen, Kathelijn F. Fischer, Roger E. G. Schutgens
Journal: American Journal of Hematology (2020)

Abstract Acquired hemophilia A (AHA) is a severe auto‐immune bleeding disorder. Treatment of AHA is burdensome and optimal management is still unresolved. Therefore a retrospective nationwide multi‐center cohort study (1992‐2018) was performed to evaluate clinical presentation and treatment efficacy and safety of AHA in the Netherlands. Multivariate logistic and Cox regression analysis was used to study independent associations between patient characteristics and clinical outcomes. A total of 143 patients (median age 73 years; 52.4% male) were included with a median follow‐up of 16.8 months (IQR 3.6‐41.5 months). First‐line immunosuppressive treatment was mostly steroid monotherapy (67.6%), steroids/cyclophosphamide (11.9%) and steroids/rituximab (11.9%), with success rates of 35.2%, 80.0% and 66.7% respectively, P &lt; .05. Eventually 75% of patients achieved complete remission (CR). A high anti‐FVIII antibody titer, severe bleeding and steroid monotherapy were associated with lower CR rates. Infections, the most important adverse event, occurred significantly more often with steroid combination therapy compared to steroids alone (38.7% vs 10.6%; P = .001). Overall mortality was 38.2%, mostly due to infections (19.2%) compared to 7.7% fatal bleeds. Advanced age, underlying malignancy and ICU admission were predictors for mortality. This study showed that AHA is characterized by significant disease‐related and treatment‐related morbidity and mortality. A high anti‐FVIII titer, severe bleeding and steroid monotherapy were associated with a lower CR rate. The efficacy of steroid combination therapies however, was overshadowed by higher infection rates and infections represented the most important cause of death. The challenging and delicate balance between treatment effectivity and safety requires ongoing monitoring of AHA and further identification of prognostic markers.
Markers of inflammation and their association with muscle strength and mass: A systematic review and meta-analysis
Authors: Camilla S.L. Tuttle, Lachlan A.N. Thang, Andrea B. Maier
Journal: Ageing Research Reviews (2020)

Chronic inflammation has been associated with sarcopenia and its components skeletal muscle strength and muscle mass. The aim of this systematic review and meta-analysis was to determine the relationship between systemic inflammation, muscle strength and/or muscle mass in adults. An electronic search using keywords such as 'acute phase proteins, cytokines and sarcopenia, muscle mass, muscle strength' was conducted via Pubmed, Web of Science and Embase from inception until the 30th of June 2020. A meta-analysis using correlation data was performed to determine the overall relationship between inflammation and muscle strength and muscle mass in adults. Overall, 168 articles; 149 cross-sectional articles (n = 76,899 participants, 47.0 % male) and 19 longitudinal articles (n = 12,295 participants, 31.9 % male) met inclusion criteria. Independent of disease state, higher levels of C reactive protein (CRP), Interleukin (IL)-6 and Tumor necrosis factor (TNF)α were associated with lower handgrip and knee extension strength (CRP; r = −0.10, p < 0.001, IL-6; r = −0.13, p < 0.001, TNFα; r = −0.08, p < 0.001 and CRP; r = −0.18, p < 0.001, IL-6; r = −0.11, p < 0.001, TNFα; r = −0.13, p < 0.001 respectively) and muscle mass (CRP; r = −0.12, p < 0.001, IL-6; r = −0.09, p < 0.001, TNFα; r = −0.15, p < 0.001). Furthermore, higher levels of systemic inflammatory markers appeared to be associated with lower muscle strength and muscle mass over time. Higher levels of circulating inflammatory markers are significantly associated with lower skeletal muscle strength and muscle mass.
1669TiP A non-randomized, open-label phase II trial evaluating efficacy and feasibility of combined treatment with trabectedin and nivolumab in patients with metastatic or inoperable soft tissue sarcomas (STS) after failure of an anthracycline-containing regimen
Authors: D.W. Müller, P. Reichardt, V. Grünwald, B. Kasper, E. Wardelmann, C.A. Schmidt, M. Walker, S.G. Decker, S-E. Al-Batran, D. Pink
Journal: Annals of Oncology (2020)
1706P Implementing oncology virtual clinics (VC) in response to COVID-19 pandemic: A transformation driven by a crisis
Authors: N. Almutairi, A. Alolayan, M. Alzahrani, A. Algarni, A. Alhadab, A. Hejazi, N. Abdelhafiz, G.E. Gmati, S. Alshehri, M. Alharbi, F. Alhemoudi, A.R. Jazieh
Journal: Annals of Oncology (2020)
1241P Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond
Authors: K. Joshi, A. Muhith, C. Milner-Watts, M. Obeid, S. Khakoo, J. Bhosle, A.R. Minchom, M. O'Brien
Journal: Annals of Oncology (2020)
Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting
Authors: Melissa Y.Y. Moey, Anna N. Tomdio, Justin D. McCallen, Lauren M. Vaughan, Kevin O’Brien, Abdul R. Naqash, Cynthia Cherry, Paul R. Walker, Blase A. Carabello
Journal: JACC CardioOncology (2020)

Immune checkpoint inhibitor (ICI)-related cardiotoxicity (iRC) is uncommon but can be fatal. There have been few reports of iRC from a rural cancer population and few data for iRC and inflammatory biomarkers. The purpose of this study was to characterize major adverse cardiac events (MACE) in ICI-treated lung cancer patients based in a rural setting and to assess the utility of C-reactive protein (CRP) and neutrophil-lymphocyte ratio (NLR) in the diagnosis of iRC. Patients with lung cancer treated with ICIs at Vidant Medical Center/East Carolina University (VMC/ECU) between 2015 and 2018 were retrospectively identified. MACE included myocarditis, non-ST-segment elevated myocardial infarction (NSTEMI), supraventricular tachycardia (SVT), and pericardial disorders. Medical history, laboratory values, pre-ICI electrocardiography (ECG), and echocardiography results were compared in patients with and without MACE. Among 196 ICI-treated patients, 23 patients (11%) developed MACE at a median of 46 days from the first ICI infusion (interquartile range [IQR]: 17 to 83 days). Patients who developed MACE experienced myocarditis (n = 9), NSTEMI (n = 3), SVT (n = 7), and pericardial disorders (n = 4). Ejection fraction was not significantly different at the time of MACE compared to that at baseline (p = 0.495). Compared to baseline values, NLR (10.9 ± 8.3 vs. 20.7 ± 4.2, respectively; p = 0.032) and CRP (42.1 ± 10.1 mg/l vs. 109.9 ± 15.6 mg/l, respectively; p = 0.010) were significantly elevated at the time of MACE. NLR and CRP were significantly elevated at the time of MACE compared to baseline values in ICI-treated patients. Larger datasets are needed to validate these findings and identify predictors of MACE that can be used in the diagnosis and management of ICI-related iRC.
1413TiP LIBRETTO-431: Selpercatinib in treatment (Tx)-naïve patients with RET fusion-positive (RET+) non-small cell lung cancer (NSCLC)
Authors: H.H.F. Loong, K. Goto, Y.Y. Elamin, B. Solomon, F.C. Santini, V. Soldatenkova, A. Sashegyi, A. Bence Lin, B.K. Lin, J. Wolf, G.R. Oxnard, C. Zhou, A. Drilon, K. Park
Journal: Annals of Oncology (2020)
Health promotion is at a crossroads with the demise of Public Health England
Authors: Michael Craig Watson, Sylvia Tilford
Journal: BMJ (2020)

We have serious concerns about health promotion after the recent announcement that Public Health England will be disbanded.12 Over the past 25 years, there have been successive reorganisations in public health alongside dramatic reductions in budgets.3456 At each upheaval skilled and experienced health promotion staff are lost.178

We are in the middle of a pandemic, and there are …
FAM46C and FNDC3A Are Multiple Myeloma Tumor Suppressors That Act in Concert to Impair Clearing of Protein Aggregates and Autophagy
Authors: Nicola Manfrini, Marilena Mancino, Annarita Miluzio, Stefania Oliveto, Matteo Balestra, Piera Calamita, Roberta Alfieri, Riccardo L. Rossi, Marco Sassoè-Pognetto, Chiara Salio, Alessandro Cuomo, Tiziana Bonaldi, Marcello Manfredi, Emilio Marengo, Elia Ranzato, Simona Martinotti, Davide Cittaro, Giovanni Tonon, Stefano Biffo
Journal: Cancer Research (2020)

Multiple myeloma is a plasma cell neoplasm characterized by the production of unfolded immunoglobulins, which cause endoplasmic reticulum (ER) stress and sensitivity to proteasome inhibition. The genomic landscape of multiple myeloma is characterized by the loss of several genes rarely mutated in other cancers that may underline specific weaknesses of multiple myeloma cells. One of these is FAM46C that is lost in more than 10% of patients with multiple myeloma. We show here that FAM46C is part of a new complex containing the ER-associated protein FNDC3A, which regulates trafficking and secretion and, by impairing autophagy, exacerbates proteostatic stress. Reconstitution of FAM46C in multiple myeloma cells that had lost it induced apoptosis and ER stress. Apoptosis was preceded by an increase of intracellular aggregates, which was not linked to increased translation of IgG mRNA, but rather to impairment of autophagy. Biochemical analysis showed that FAM46C requires interaction with ER bound protein FNDC3A to reside in the cytoplasmic side of the ER. FNDC3A was lost in some multiple myeloma cell lines. Importantly, depletion of FNDC3A increased the fitness of FAM46C-expressing cells and expression of FNDC3A in cells that had lost it recapitulated the effects of FAM46C, inducing aggregates and apoptosis. FAM46C and FNDC3A formed a complex that modulates secretion routes, increasing lysosome exocytosis. The cellular landscape generated by FAM46C/FNDC3A expression predicted sensitivity to sphingosine kinase inhibition. These results suggest that multiple myeloma cells remodel their trafficking machinery to cope with ER stress. SIGNIFICANCE: This study identifies a new multiple myeloma-specific tumor suppressor complex that regulates autophagy and unconventional secretion, highlighting the sensitivity of multiple myeloma cells to the accumulation of protein aggregates.
1868P Efficacy and safety of naloxegol in patients with cancer with opioid-induced constipation with laxative-inadequate response: A long-term, real-world study
Authors: C. Beato Zambrano, M. Cobo Dols, L. Cabezón Gutiérrez, R. Chicas-Sett, M.I. Blancas López-Barajas, F.J. García-Navalón, J.L. Firvida Pérez, S. Llorens Torromé, P. Togores Torres, I. Delgado Mingorance, A. Giraldo Marín, A. Librán Oriol, A. Paredes Lario, P. Sánchez Mauriño, O. Higuera Gómez, D. Moreno Muñoz, I. Huerta González, A. Sanz Yagüe, B. Soler López
Journal: Annals of Oncology (2020)
1255TiP CheckMate 73L: A phase III study comparing nivolumab (NIVO) plus concurrent chemoradiotherapy (CCRT) followed by NIVO ± ipilimumab (IPI) versus CCRT followed by durvalumab (DURV) for previously untreated, locally advanced (LA) stage III non-small cell lung cancer (NSCLC)
Authors: D. De Ruysscher, S.S. Ramalingam, J. Urbanic, D.E. Gerber, D.S.W. Tan, J. Cai, A. Li, S. Peters
Journal: Annals of Oncology (2020)
1027MO ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (pts) with refractory solid tumours (ARTISTRY-1)
Authors: U.N. Vaishampayan, J. Muzaffar, V. Velcheti, I. Winer, C.J. Hoimes, S.D. Rosen, A. Spreafico, D.F. McDermott, Q.S-C. Chu, O. Dumas, L. Gilbert, H. Hirte, K.K. Curtis, Y. Du, I. Bidollari, L. Sun, E. Putiri, H.C. Losey, B. Dezube, M.S. Ernstoff
Journal: Annals of Oncology (2020)
A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma
Authors: Kirill V. Lepik, Liudmila V. Fedorova, Elena V. Kondakova, Yuri R. Zalyalov, Elena V. Babenko, Elena E. Lepik, Polina V. Kotselyabina, Anastasia V. Beynarovich, Marina O. Popova, Nikita P. Volkov, Lilia V. Stelmakh, Vadim V. Baykov, Ivan S. Moiseev, Natalia B. Mikhailova, Alexander D. Kulagin, Boris V. Afanasyev
Journal: HemaSphere (2020)

The introduction of nivolumab has changed the landscape of relapsed/refractory classical Hodgkin lymphoma (r/r cHL) treatment. Despite its clinical importance, this therapy may remain inaccessible for a significant number of patients worldwide, especially in low-income countries, due to its high cost. The results of pharmacokinetic analysis and clinical observations suggest the potential efficacy of low dose nivolumab in r/r cHL patients. The aim of this trial was to assess the efficacy and safety of nivolumab at a fixed dose of 40 mg in patients with r/r cHL. The study included 30 patients with r/r cHL, treated with 40 mg nivolumab every 2 weeks. The median dose of nivolumab per kilogram bodyweight was 0.59 mg/kg (0.4-1 mg/kg). Median follow up was 19.2 months (range 12.7-25.4). The objective response rate was 70%, with 13 (43.3%) patients achieving a complete response. Median PFS was 18.4 months (95% CI, 11.3 to 18.5 months) with 18-month PFS of 53.6% (95% CI, 32%-71%). At the time of analysis, 96.7% of patients were alive with a median OS not reached. Severe (grade 3-5) adverse events were observed in 4 patients (13.3%). Nivolumab in a fixed dose of 40 mg was efficient in patients with r/r cHL, independent from dose per kg bodyweight. The results of this study are in good agreement with previously reported data and create a rationale for further studies aimed to define the optimal dosing regimen of nivolumab for the treatment of r/r cHL. Registered at www.clinicaltrials.gov (NCT03343665).
1102P Clinical benefit in BRAFV600 mutation-positive melanoma defined by programmed death ligand 1 (PD-L1) and/or lactate dehydrogenase (LDH) status: Exploratory analyses from the IMspire150 study
Authors: P.A. Ascierto, C. Robert, K. Lewis, R. Gutzmer, D. Stroyakovskiy, H.J. Gogas, S. Protsenko, R.P. Pereira, T. Eigentler, P. Rutkowski, L. Demidov, G. Moiseevich Manikhas, V. McNally, H. Forbes, K. Shah, Y. Yan, G. McArthur
Journal: Annals of Oncology (2020)
892MO High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with HIV-related lymphoma
Authors: M. Popova, I. Tsygankov, Y. Rogacheva, K. Lepik, Y. Zalylov, L. Stelmah, V. Baykov, S. Bondarenko, N. Mikhaylova
Journal: Annals of Oncology (2020)
1960P Differential induction of gene expression may explain differences in reported adverse event profiles between the FGFR-inhibitors derazantinib and erdafitinib: An analysis in safety relevant normal tissues from urothelial cancer (UC) patient-derived mouse xenograft (PDX) models
Authors: P. McSheehy, J. Guo, K. Beebe, J.R. Eisner, S. Anderson, S. Braun, M. Engelhardt, L. Kellenberger, H. Lane, M. Milburn
Journal: Annals of Oncology (2020)
242P Reclassification of variants of unknown significance in BRCA 1/2 genes for the improvement of care quality in oncological genetic council units
Authors: A. Olivares Hernandez, M.D.R. Vidal Tocino, L. Figuero Pérez, R.A. Escala Cornejo, T. Martín Gómez, E.M. Sánchez Tapia, J. Pérez García, J. Claros Ampuero, E. Escalera Martín, E. Terán Brage, Á. López Gutiérrez, B. Barrios Collado, C.A. Rodríguez Sáchez, A. Amores Martín, M. Muñoz García, R. Gonzalez Sarmiento, J.J. Cruz Hernández
Journal: Annals of Oncology (2020)
1348P Efficacy and safety of ceritinib 450 mg-fed vs 750 mg-fasted in Asian patients (pts) with ALK+ non-small cell lung cancer (NSCLC) in the ASCEND-8 trial
Authors: B.C. Chul Cho, D-W. Kim, U. Batra, K. Park, S-W. Kim, C.T. Yang, V. Pie Jye, V. Sriuranpong, K.G. Babu, K. Amin, Y. Wang, L. Wang, M. Bhering, S. Lucien Geater
Journal: Annals of Oncology (2020)